Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer.

Xing, Puyuan

Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer. [electronic resource] - Thoracic cancer 07 2018 - 805-813 p. digital

Publication Type: Journal Article

1759-7714

10.1111/1759-7714.12650 doi


Adult
Aged
Anaplastic Lymphoma Kinase--genetics
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Bevacizumab--administration & dosage
Brain Neoplasms--drug therapy
Carcinoma, Non-Small-Cell Lung--drug therapy
Drug-Related Side Effects and Adverse Reactions--drug therapy
ErbB Receptors--genetics
Female
Gene Expression Regulation, Neoplastic--drug effects
Humans
Male
Middle Aged
Neoplasm Staging
Progression-Free Survival
Retrospective Studies